tiprankstipranks
Trending News
More News >

Sinco Pharmaceuticals Reports Revenue Growth Amid Rising Costs

Story Highlights
Sinco Pharmaceuticals Reports Revenue Growth Amid Rising Costs

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ).

Sinco Pharmaceuticals Holdings Ltd. reported an 11.1% increase in revenue to RMB2,821.3 million for the year ending December 31, 2024, driven by higher sales volumes of human albumin solutions. However, the company’s gross profit decreased due to rising costs, leading to a slight decline in net profit to RMB42.0 million. The board proposed a reduced final dividend of HK0.20 cents per share, reflecting a cautious approach amid cost pressures.

More about Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Ltd. is a company incorporated under the laws of the Cayman Islands, operating in the pharmaceutical industry. The company primarily focuses on the production and sale of pharmaceutical products, with a significant emphasis on human albumin solutions.

YTD Price Performance: 7.50%

Average Trading Volume: 479,649

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$437.1M

See more data about 6833 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1